Table 1—

Baseline characteristics and lung function decline of lymphangioleiomyomatosis patients treated or not with statins

Statin#No statinp-value+
Age yrs53.1±1.0941.2±0.54<0.001
Follow-up yrs2.5±0.294.3±0.17<0.001
Initial FEV1 % pred72.3±3.8479.1±1.480.086
Initial DL,CO % pred65.7±3.4077.4±1.510.003
Yearly change in FEV1 % pred-0.4±1.06-2.4±0.330.039§
Yearly change in DL,CO % pred-3.8±0.97-3.2±0.340.549
  • Data are presented as mean±se, unless otherwise stated. FEV1: forced expiratory volume in 1 s; % pred: % predicted; DL,CO: diffusing capacity of the lung for carbon monoxide. #: n = 42; : n = 293; +: unadjusted; §: statin was not a significant predictor of FEV1 % rate after adjusting for age (p = 0.718).